Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Genedrive Share Price
  4. Genedrive Share Regulatory News
  5. Investor presentation

Pin to quick picksGenedrive Regulatory News (GDR)

Genedrive Information

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    0.025 (2.04%)
Bid:
1.20
Ask:
1.35
Spread: 0.15 (12.50%)
Market Cap: £20.07m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Investor presentation

10 Jun 2020 07:00

RNS Number : 4507P
Genedrive PLC
10 June 2020
 

genedrive plc

("genedrive" or the "Company")

 

Investor presentation

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that David Budd, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.

 

The event will be held on Friday, 12 June 2020 at 2pm. Please register your interest at https://voxmarkets.brand.live/c/genedrive-plc.

 

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently launched a high throughput SARS-CoV-2 assay and has a Genedrive® Point of Care version of the assay in development, both based on Genedrive® PCR chemistry.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFLFIRRFIAIII
891011121314151617
Date   Source Headline
18th May 201512:45 pmRNSNIH Response to UMB proposal
11th May 20153:37 pmRNSAdditional Listing
11th May 201511:53 amRNSDirectorate Change
23rd Apr 20157:00 amRNSRegulatory Approval
13th Apr 20157:00 amRNSUpdate re Indian regulatory approval
2nd Apr 20154:55 pmRNSDirector/PDMR Shareholding
30th Mar 20159:30 amRNSExtension of Director's Options Exercise Period
26th Mar 20157:00 amRNSHalf Yearly Report
11th Feb 20153:21 pmRNSHolding(s) in Company
6th Feb 20157:48 amRNSNotice of Interim Results
12th Jan 201512:19 pmRNSResult of AGM
6th Jan 20152:50 pmRNSDirector/PDMR Shareholding
18th Dec 20149:08 amRNSGrant of Options
15th Dec 20145:26 pmRNSNotice of AGM
24th Nov 201410:00 amRNSDirectorate Change
28th Oct 20147:01 amRNSSuccessful Completion of Genedrive Trials
28th Oct 20147:00 amRNSFinal Results
7th Oct 20147:00 amRNSNotice of Results
28th Jul 20149:56 amRNSAdditional Listing
22nd Jul 20147:05 amRNSPre Close Trading Update
22nd Jul 20147:00 amRNSCollaborative funding agreement with GHIF
9th May 20149:22 amRNSHolding(s) in Company
8th May 20145:14 pmRNSHolding(s) in Company
1st May 20144:37 pmRNSAdditional Listing
23rd Apr 20148:45 amRNSAdditional Listing
8th Apr 20146:21 pmRNSAdditional Listing
7th Apr 20144:44 pmRNSDirector/PDMR Shareholding
25th Mar 20147:00 amRNSHalf Yearly Report
17th Feb 20149:34 amRNSNotice of Results
3rd Feb 20143:26 pmRNSHolding(s) in Company
3rd Feb 20142:43 pmRNSHolding(s) in Company
27th Jan 20147:00 amRNSDirectorate Change
7th Jan 20142:12 pmRNSDirectors' Shareholdings
6th Jan 20144:33 pmRNSAdditional Listing
18th Dec 201312:46 pmRNSResult of AGM
18th Dec 20137:00 amRNSRe Agreement
16th Dec 20133:36 pmRNSAdditional Listing
3rd Dec 20131:30 pmRNSDirector/PDMR Shareholding
26th Nov 20134:27 pmRNSAdditional Listing
26th Nov 20137:00 amRNSAnnual Report & Accounts and Notice of AGM
22nd Oct 20137:00 amRNSFinal Results
11th Oct 20138:49 amRNSDirectorate Change
7th Oct 20138:29 amRNSDirector/PDMR Shareholding
1st Oct 20131:06 pmRNSPreliminary Results Date
9th Sep 20137:00 amRNSTrading Update
23rd Aug 20132:38 pmRNSHolding(s) in Company
8th Aug 20133:09 pmRNSHolding(s) in Company
8th Aug 20137:00 amRNSEPISTEM RECEIVES PRESTIGIOUS FP7 GRANT AWARD
1st Aug 20137:00 amRNSTrading Update
1st Jul 20134:04 pmRNSDirector/PDMR Shareholding
891011121314151617

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
MXEU
Inv Msci Europe
LSE
0.51%
SCIN
SCIN.L
LSE
0.00%
Trending
BSFA
Bio-Sustainable Future Enterprises
LSE
0.00%
GEX
Georgina Energy
LSE
1.69%
PREM
Premier African Minerals
LSE
-16.00%
PANR
Pantheon Resources plc
LSE
31.07%
ALRT
Defence Holdings
LSE
0.00%